# Graves Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/graves-disease

> 21 upcoming FDA catalysts in Graves Disease: imeroprubart (IMVT) on 2027 (topline data readout); LCA-0321 (LYCA) on 2027 (interim data readout); Wayrilz (rilzabrutinib, SNY) on Feb to May 2027 (topline data readout); Wayrilz (rilzabrutinib, SNY) on February 2027 (primary completion); and 17 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for Graves Disease?

21 upcoming FDA catalysts in Graves Disease: imeroprubart (IMVT) on 2027 (topline data readout); LCA-0321 (LYCA) on 2027 (interim data readout); Wayrilz (rilzabrutinib, SNY) on Feb to May 2027 (topline data readout); Wayrilz (rilzabrutinib, SNY) on February 2027 (primary completion); and 17 more. Press release filed with the SEC (EX-99): "The Company expects to report topline data across potentially registrational trials of IMVT-1402 in Graves' disease (GD) and myasthenia gravis (MG) in calendar year 2027." [Calendar and source filings](https://sec-api.dev/indications/graves-disease)

Source: Press release filed with the SEC (EX-99), accession 0001764013-26-000121, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000121/exhibit9912026119.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/indications/graves-disease#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 25, 2025 | [Imvt-1401 (batoclimab) primary completion](https://sec-api.dev/pdufa/imvt-1401-batoclimab) | IMVT | Graves Disease | completed | "NCT05907668 (A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05907668)) |
| May 2026 | [MoDE (BHV-1300) trial start](https://sec-api.dev/pdufa/bhv-1300) | BHVN | Graves' disease | completed | "•Presented new patient data from the MoDE platform in Graves' disease; initiated pivotal study: In May 2026, the Company presented new clinical data from an ongoing Phase 1b study of BHV-1300 in patients with Graves' disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/a2026q2bhvnearningsprex991.htm)) |
| August 13, 2026 | [Imvt-1401 (batoclimab) topline data readout](https://sec-api.dev/pdufa/imvt-1401-batoclimab) | IMVT | Graves Disease | completed | "NCT05907668 (A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05907668?tab=results)) |
| Q4 2026 | [VRDN-292 trial start](https://sec-api.dev/pdufa/vrdn-292) | VRDN | Graves' disease | scheduled | "- VRDN-292, a potential best-in-class TSHR inhibitor, expected to initiate a phase 1 clinical trial in patients in Q4 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526446200/d176865dex991.htm)) |
| 2027 | [Imeroprubart topline data readout](https://sec-api.dev/pdufa/imeroprubart) | IMVT | Graves' Disease | scheduled | "The Company expects to report topline data across potentially registrational trials of IMVT-1402 in Graves' disease (GD) and myasthenia gravis (MG) in calendar year 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000121/exhibit9912026119.htm)) |
| 2027 | [LCA-0321 interim data readout](https://sec-api.dev/pdufa/lca-0321) | LYCA | Graves' disease | scheduled | "We are conducting a Phase 1 clinical trial of LCA-0321 in patients with Graves' disease, and we expect initial data in 2027." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1806540/000162828026067048/lyciatherapeutics-424b4.htm)) |
| Feb to May 2027 | [Wayrilz (rilzabrutinib) topline data readout](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Graves' Disease | scheduled | "NCT06984627 (A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06984627)) |
| February 2027 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Graves' Disease | scheduled | "NCT06984627 (A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06984627)) |
| May 2027 | [IMVT-1402 primary completion](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Graves' Disease | scheduled | "NCT07018323 (A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07018323)) |
| May to Aug 2027 | [IMVT-1402 topline data readout](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Graves' Disease | scheduled | "NCT07018323 (A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07018323)) |
| 2H 2027 | [YB-101 topline data readout](https://sec-api.dev/pdufa/yb-101) | YARW | Graves' disease | scheduled | "Enrollment ongoing in the Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves' disease (with or without concomitant thyroid eye disease); Phase 2a topline results expected in the second half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000017/yarw-q32026earningsrelease.htm)) |
| December 2027 | [Experimental: yb-101 primary completion](https://sec-api.dev/pdufa/experimental-yb-101) | YARW | Graves' Disease | scheduled | "NCT07682896 (Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Yarrow Bioscience, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07682896)) |
| Dec 2027 to Mar 2028 | [Experimental: yb-101 topline data readout](https://sec-api.dev/pdufa/experimental-yb-101) | YARW | Graves' Disease | scheduled | "NCT07682896 (Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Yarrow Bioscience, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07682896)) |
| January 2028 | [MoDE (BHV-1300) primary completion](https://sec-api.dev/pdufa/bhv-1300) | BHVN | Graves Disease | scheduled | "NCT07661056 (Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07661056)) |
| Jan to Apr 2028 | [MoDE (BHV-1300) topline data readout](https://sec-api.dev/pdufa/bhv-1300) | BHVN | Graves Disease | scheduled | "NCT07661056 (Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07661056)) |
| Jan to Apr 2028 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Graves' Disease | scheduled | "NCT07722546 (A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-31 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07722546)) |
| January 2028 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Graves' Disease | scheduled | "NCT07722546 (A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-31 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07722546)) |
| June 2028 | [IMVT-1402 primary completion](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Graves' Disease | scheduled | "NCT06727604 (A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06727604)) |
| Jun to Sep 2028 | [IMVT-1402 topline data readout](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Graves' Disease | scheduled | "NCT06727604 (A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06727604)) |
| June 2028 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Graves Disease | scheduled | "NCT07596849 (A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596849)) |
| Jun to Sep 2028 | [Efgartigimod ph20 sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Graves Disease | scheduled | "NCT07596849 (A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596849)) |
| December 2028 | [MoDE (BHV-1300) primary completion](https://sec-api.dev/pdufa/bhv-1300) | BHVN | Graves' Disease | scheduled | "NCT07901244 (An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07901244)) |
| Dec 2028 to Mar 2029 | [MoDE (BHV-1300) topline data readout](https://sec-api.dev/pdufa/bhv-1300) | BHVN | Graves' Disease | scheduled | "NCT07901244 (An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07901244)) |
| March 2030 | [IMVT-1402 primary completion](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Graves' Disease | scheduled | "NCT07286006 (A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286006)) |
| Mar to Jun 2030 | [IMVT-1402 topline data readout](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Graves' Disease | scheduled | "NCT07286006 (A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286006)) |

## Drugs

- [Imvt-1401 (batoclimab)](https://sec-api.dev/pdufa/imvt-1401-batoclimab) (IMVT)
- [MoDE (BHV-1300)](https://sec-api.dev/pdufa/bhv-1300) (BHVN)
- [VRDN-292](https://sec-api.dev/pdufa/vrdn-292) (VRDN)
- [Imeroprubart](https://sec-api.dev/pdufa/imeroprubart) (IMVT)
- [LCA-0321](https://sec-api.dev/pdufa/lca-0321) (LYCA)
- [Wayrilz (rilzabrutinib)](https://sec-api.dev/pdufa/rilzabrutinib) (SNY)
- [IMVT-1402](https://sec-api.dev/pdufa/imvt-1402) (IMVT)
- [YB-101](https://sec-api.dev/pdufa/yb-101) (YARW)
- [Experimental: yb-101](https://sec-api.dev/pdufa/experimental-yb-101) (YARW)
- [Felzartamab](https://sec-api.dev/pdufa/felzartamab) (BIIB)
- [Efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) (ARGX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/graves-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Graves Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/graves-disease

```bibtex
@misc{secapidev_indications_graves_disease_20261116,
  title        = {Graves Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/graves-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_graves_disease_20261116","title":"Graves Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/graves-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
